Raffles Medical Group Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Raffles Medical Group kazanç ve gelirin sırasıyla yıllık 12.2% ve 4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 11.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 7.2% olacağı tahmin edilmektedir.

Anahtar bilgiler

12.2%

Kazanç büyüme oranı

11.2%

EPS büyüme oranı

Healthcare kazanç büyümesi	19.0%
Gelir büyüme oranı	4.0%
Gelecekteki özkaynak getirisi	7.2%
Analist kapsamı	Good
Son güncelleme	05 Dec 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Raffles Medical Group (SGX:BSL) Is Reducing Its Dividend To SGD0.024

May 09

Raffles Medical Group's (SGX:BSL) Dividend Is Being Reduced To SGD0.024

Apr 25

Raffles Medical Group's (SGX:BSL) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 10

Estimating The Intrinsic Value Of Raffles Medical Group Ltd (SGX:BSL)

Nov 16

Raffles Medical Group (SGX:BSL) Is Doing The Right Things To Multiply Its Share Price

Nov 03

Is There An Opportunity With Raffles Medical Group Ltd's (SGX:BSL) 25% Undervaluation?

Oct 09

Is Raffles Medical Group (SGX:BSL) A Risky Investment?

Sep 26

The Return Trends At Raffles Medical Group (SGX:BSL) Look Promising

Sep 01

With EPS Growth And More, Raffles Medical Group (SGX:BSL) Makes An Interesting Case

Aug 20

Raffles Medical Group (SGX:BSL) Has Some Way To Go To Become A Multi-Bagger

Jun 01

Raffles Medical Group (SGX:BSL) Is Increasing Its Dividend To S$0.028

May 02

We Think Raffles Medical Group (SGX:BSL) Can Manage Its Debt With Ease

Apr 18

Slowing Rates Of Return At Raffles Medical Group (SGX:BSL) Leave Little Room For Excitement

Feb 21

Raffles Medical Group (SGX:BSL) Seems To Use Debt Rather Sparingly

Oct 14

Raffles Medical Group (SGX:BSL) Has Some Way To Go To Become A Multi-Bagger

Oct 02

At S$1.40, Is Raffles Medical Group Ltd (SGX:BSL) Worth Looking At Closely?

Sep 21

Here's Why I Think Raffles Medical Group (SGX:BSL) Is An Interesting Stock

Aug 12

Here's What's Concerning About Raffles Medical Group's (SGX:BSL) Returns On Capital

Jul 01

At S$1.08, Is It Time To Put Raffles Medical Group Ltd (SGX:BSL) On Your Watch List?

May 25

Kazanç ve Gelir Büyüme Tahminleri

SGX:BSL - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (SGD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	821	82	106	122	5
12/31/2025	785	77	100	122	8
12/31/2024	741	68	-8	98	8
6/30/2024	703	61	72	97	N/A
3/31/2024	706	76	120	143	N/A
12/31/2023	708	90	167	189	N/A
9/30/2023	747	117	166	189	N/A
6/30/2023	786	144	165	188	N/A
3/31/2023	805	143	168	192	N/A
12/31/2022	825	143	171	196	N/A
9/30/2022	808	124	179	204	N/A
6/30/2022	791	104	188	212	N/A
3/31/2022	758	94	148	186	N/A
12/31/2021	725	84	107	160	N/A
9/30/2021	698	86	108	171	N/A
6/30/2021	671	88	109	181	N/A
3/31/2021	619	77	91	157	N/A
12/31/2020	568	66	73	133	N/A
9/30/2020	541	60	42	121	N/A
6/30/2020	508	50	23	105	N/A
3/31/2020	514	55	21	107	N/A
12/31/2019	522	60	13	111	N/A
9/30/2019	514	63	16	93	N/A
6/30/2019	504	66	28	92	N/A
3/31/2019	497	69	35	89	N/A
12/31/2018	489	71	62	94	N/A
9/30/2018	484	71	63	88	N/A
6/30/2018	483	71	57	81	N/A
3/31/2018	483	71	N/A	88	N/A
12/31/2017	478	71	N/A	83	N/A
9/30/2017	473	70	N/A	81	N/A
6/30/2017	473	70	N/A	65	N/A
3/31/2017	472	70	N/A	63	N/A
12/31/2016	474	70	N/A	79	N/A
9/30/2016	470	71	N/A	83	N/A
6/30/2016	452	71	N/A	92	N/A
3/31/2016	432	70	N/A	91	N/A
12/31/2015	411	69	N/A	73	N/A
9/30/2015	396	69	N/A	86	N/A
6/30/2015	389	68	N/A	79	N/A
3/31/2015	382	68	N/A	94	N/A
12/31/2014	375	68	N/A	93	N/A
9/30/2014	363	89	N/A	66	N/A
6/30/2014	353	87	N/A	83	N/A
3/31/2014	347	86	N/A	71	N/A
12/31/2013	341	85	N/A	71	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: BSL 'nin tahmini kazanç büyümesi (yıllık 12.2% ) tasarruf oranının ( 2.2% ) üzerindedir.

Kazançlar ve Piyasa: BSL şirketinin kazançlarının (yıllık 12.2% ) SG pazarından (yıllık 11.3% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: BSL şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: BSL şirketinin gelirinin (yıllık 4% ) SG pazarından (yıllık 3.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: BSL şirketinin gelirinin (yıllık 4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: BSL 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 7.2 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/27 04:53
Gün Sonu Hisse Fiyatı	2024/12/27 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Raffles Medical Group Ltd 20 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Mak	CGS International
Patrick Yau	Citigroup Inc
Horng Han Low	CLSA

Raffles Medical Group Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 12% to S$1.14

Consensus EPS estimates fall by 21%

Price target increased by 8.1% to S$1.72

Price target increased to S$1.52

Price target decreased to S$1.39

Price target decreased to S$1.39

Recent updates

Executive Chairman & CEO recently bought S$602k worth of stock

Executive Chairman & CEO recently bought S$861k worth of stock

Executive Chairman & CEO recently bought S$1.3m worth of stock

Executive Chairman & CEO recently bought S$979k worth of stock

Executive Chairman & CEO recently bought S$1.5m worth of stock

Executive Chairman & CEO recently bought S$700k worth of stock

New minor risk - Dividend sustainability

Executive Chairman & CEO recently bought S$1.3m worth of stock

First half 2024 earnings released: EPS: S$0.017 (vs S$0.032 in 1H 2023)

Executive Chairman & CEO recently bought S$1.5m worth of stock

Raffles Medical Group Ltd to Report First Half, 2024 Results on Jul 29, 2024

Raffles Medical Group (SGX:BSL) Is Reducing Its Dividend To SGD0.024

Executive Chairman & CEO recently bought S$500k worth of stock

Upcoming dividend of S$0.024 per share

Raffles Medical Group Ltd Approves One-Tier Tax Exempt Final Dividend for the Year Ended 31 December 2023, Payable on May 23, 2024

Raffles Medical Group's (SGX:BSL) Dividend Is Being Reduced To SGD0.024

Raffles Medical Group's (SGX:BSL) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Full year 2023 earnings: EPS misses analyst expectations

Now 20% undervalued

Raffles Medical Group Ltd Proposes Final Dividend for the Year Ended 31 December 2023, Payable on May 23, 2024

Price target decreased by 12% to S$1.14

Consensus EPS estimates fall by 21%

Executive Chairman & CEO recently bought S$3.6m worth of stock

Dividend of S$0.024 announced

Raffles Medical Group Ltd, Annual General Meeting, Apr 26, 2024

Estimating The Intrinsic Value Of Raffles Medical Group Ltd (SGX:BSL)

Investor sentiment deteriorates as stock falls 15%

Raffles Medical Group (SGX:BSL) Is Doing The Right Things To Multiply Its Share Price

Here's Why Raffles Medical Group (SGX:BSL) Has Caught The Eye Of Investors

Raffles Medical Group Ltd Announces Resignation of Soo Yu-Han Jessica as Joint Company Secretary, Effective 8 August 2023

High number of new directors

First half 2023 earnings released: EPS: S$0.032 (vs S$0.032 in 1H 2022)

Raffles Medical Group Ltd Announces Appointment of Lu Liangjian as Non-Executive and Non-Independent Director

The Return Trends At Raffles Medical Group (SGX:BSL) Look Promising

Raffles Medical Group Ltd to Report First Half, 2023 Results on Jul 31, 2023

Raffles Medical Group (SGX:BSL) Could Easily Take On More Debt

A Look At The Fair Value Of Raffles Medical Group Ltd (SGX:BSL)

Is Now The Time To Put Raffles Medical Group (SGX:BSL) On Your Watchlist?

Upcoming dividend of S$0.038 per share at 2.6% yield

Raffles Medical Group (SGX:BSL) Is Increasing Its Dividend To SGD0.038

Full year 2022 earnings: Revenues in line with analyst expectations

Raffles Medical Group (SGX:BSL) Might Have The Makings Of A Multi-Bagger

Price target increased by 8.1% to S$1.72

Full year 2022 earnings: EPS exceeds analyst expectations

Estimating The Intrinsic Value Of Raffles Medical Group Ltd (SGX:BSL)

Raffles Medical Group Ltd to Report Fiscal Year 2022 Results on Feb 27, 2023

Returns At Raffles Medical Group (SGX:BSL) Are On The Way Up

Do Raffles Medical Group's (SGX:BSL) Earnings Warrant Your Attention?

Now 21% undervalued

Is There An Opportunity With Raffles Medical Group Ltd's (SGX:BSL) 25% Undervaluation?

Is Raffles Medical Group (SGX:BSL) A Risky Investment?

Now 21% undervalued

The Return Trends At Raffles Medical Group (SGX:BSL) Look Promising

With EPS Growth And More, Raffles Medical Group (SGX:BSL) Makes An Interesting Case

Now 20% undervalued

Investor sentiment improved over the past week

Price target increased to S$1.52

Executive Chairman & CEO recently bought S$63k worth of stock

First half 2022 earnings released

Raffles Medical Group Ltd to Report First Half, 2022 Results on Aug 01, 2022

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Raffles Medical Group (SGX:BSL) Has Some Way To Go To Become A Multi-Bagger

Raffles Medical Group Ltd Approves Final Dividend for the Year Ended 31 December 2021

Raffles Medical Group Ltd Approves Final Dividend for the Year Ended 31 December 2021

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of S$0.028 per share

Raffles Medical Group (SGX:BSL) Is Increasing Its Dividend To S$0.028